{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:14:41Z","timestamp":1790734481461,"version":"4.1.0"},"reference-count":48,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R33ES025673"],"award-info":[{"award-number":["R33ES025673"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F30DK126310"],"award-info":[{"award-number":["F30DK126310"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK084321"],"award-info":[{"award-number":["R01DK084321"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK111538"],"award-info":[{"award-number":["R01DK111538"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK113093"],"award-info":[{"award-number":["R01DK113093"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK130328"],"award-info":[{"award-number":["R01DK130328"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK120456"],"award-info":[{"award-number":["U01DK120456"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["G-1912-03552"],"award-info":[{"award-number":["G-1912-03552"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["G-2018PG-T1D034"],"award-info":[{"award-number":["G-2018PG-T1D034"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI148675"],"award-info":[{"award-number":["R01AI148675"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Low-dose IL-2 is a promising immunotherapy in clinical trials for treating type 1 diabetes. A new IL-2 analog, IL-2\/CD25 fusion protein, has been shown to more efficiently delay or prevent diabetes in NOD mice by expanding the population of activated regulatory T cells. This therapy is intended for use before clinical diagnosis, in the early stages of type 1 diabetes progression. During this prediabetic period, there is a chronic decline in \u03b2-cell function that has long-term implications for disease pathogenesis. Yet, to date, the effects of IL-2\/CD25 on \u03b2-cell function have not been evaluated. In this study, we treated prediabetic NOD mice with low-dose mouse IL-2\/CD25 over 5 weeks and determined its impact on \u03b2-cell function. This treatment limited the progressive impairment of glucose tolerance and insulin secretion typical of the later stages of prediabetes. Intracellular Ca2+ responses to glucose in \u03b2-cells became more robust and synchronous, indicating that changing the local immune cell infiltrate with IL-2\/CD25 preserved \u03b2-cell function even after treatment cessation. Our study thus provides mechanistic insight and serves as a steppingstone for future research using low-dose IL-2\/CD25 immunotherapy in patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Article Highlights<\/jats:title>\n                  <jats:p>Immunotherapies such as IL-2\/CD25 are known to prevent or delay diabetes. However, their impact on individual \u03b2-cell function is not yet understood. Female NOD mice progress from stage 1 to 2 pre\u2013type 1 diabetes between 12 and 17 weeks. Treatment with mouse IL-2 (mIL-2)\/CD25 prevents this progression even after treatment cessation. Individual \u03b2-cell function (measured via intracellular Ca2+ responses to glucose) declines during the pathogenesis of type 1 diabetes. Treatment with mIL-2\/CD25 therapy limits \u03b2-cell dysfunction, and function continues to improve after treatment cessation. Insulin secretion is improved with mIL-2\/CD25 therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db22-0482","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T15:24:31Z","timestamp":1679325871000},"page":"769-780","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":11,"title":["Immunotherapy With Low-Dose IL-2\/CD25 Prevents \u03b2-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice"],"prefix":"10.2337","volume":"72","author":[{"given":"Farhan M.","family":"Qureshi","sequence":"first","affiliation":[{"name":"1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"},{"name":"2Department of Molecular, Cell and Developmental Biology, University of Miami Miller School of Medicine, Miami, FL"},{"name":"3Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Panzer","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"P\u00f5der","sequence":"additional","affiliation":[{"name":"4Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-0434","authenticated-orcid":false,"given":"Thomas R.","family":"Malek","sequence":"additional","affiliation":[{"name":"4Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-3529","authenticated-orcid":false,"given":"Alejandro","family":"Caicedo","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"},{"name":"2Department of Molecular, Cell and Developmental Biology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"2023051919002502700_B1","unstructured":"World Health Organization\n          . Diabetes fact sheet, 2021. Accessed 10 May 2022. Available from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes"},{"key":"2023051919002502700_B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","article-title":"New frontiers in the treatment of type 1 diabetes","volume":"31","author":"Warshauer","year":"2020","journal-title":"Cell Metab"},{"key":"2023051919002502700_B3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11892-016-0739-1","article-title":"Promoting immune regulation in type 1 diabetes using low-dose interleukin-2","volume":"16","author":"Dwyer","year":"2016","journal-title":"Curr Diab Rep"},{"key":"2023051919002502700_B4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2023051919002502700_B5","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","article-title":"IL-2\/CD25: A long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells","volume":"201","author":"Ward","year":"2018","journal-title":"J Immunol"},{"key":"2023051919002502700_B6","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2337\/db20-0186","article-title":"Persistent IL-2 receptor signaling by IL-2\/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms","volume":"69","author":"Ward","year":"2020","journal-title":"Diabetes"},{"key":"2023051919002502700_B7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.molmet.2017.06.019","article-title":"Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis","volume":"6","author":"Chen","year":"2017","journal-title":"Mol Metab"},{"key":"2023051919002502700_B8","doi-asserted-by":"crossref","first-page":"e120877","DOI":"10.1172\/jci.insight.120877","article-title":"\u03b2 Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis","volume":"3","author":"Evans-Molina","year":"2018","journal-title":"JCI Insight"},{"key":"2023051919002502700_B9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI78142","article-title":"\u03b2 Cell death and dysfunction during type 1 diabetes development in at-risk individuals","volume":"125","author":"Herold","year":"2015","journal-title":"J Clin Invest"},{"key":"2023051919002502700_B10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/db11-0373","article-title":"Progressive erosion of \u03b2-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes","volume":"60","author":"Ize-Ludlow","year":"2011","journal-title":"Diabetes"},{"key":"2023051919002502700_B11","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"2023051919002502700_B12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2009.21","article-title":"The role of inflammation in insulitis and beta-cell loss in type 1 diabetes","volume":"5","author":"Eizirik","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"2023051919002502700_B13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ceca.2011.08.005","article-title":"The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes","volume":"50","author":"Ramadan","year":"2011","journal-title":"Cell Calcium"},{"key":"2023051919002502700_B14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cmet.2017.01.005","article-title":"\u03b2 Cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice","volume":"25","author":"Rui","year":"2017","journal-title":"Cell Metab"},{"key":"2023051919002502700_B15","doi-asserted-by":"crossref","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2023051919002502700_B16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023051919002502700_B17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023051919002502700_B18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.clinthera.2016.04.032","article-title":"Correlation among hypoglycemia, glycemic variability, and C-peptide preservation after alefacept therapy in patients with type 1 diabetes mellitus: analysis of data from the Immune Tolerance Network T1DAL Trial","volume":"38","author":"Pinckney","year":"2016","journal-title":"Clin Ther"},{"key":"2023051919002502700_B19","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.2337\/dc13-0418","article-title":"Residual \u03b2-cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents","volume":"36","author":"S\u00f8rensen","year":"2013","journal-title":"Diabetes Care"},{"key":"2023051919002502700_B20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"2023051919002502700_B21","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/nprot.2014.195","article-title":"Using pancreas tissue slices for in situ studies of islet of Langerhans and acinar cell biology","volume":"9","author":"Marciniak","year":"2014","journal-title":"Nat Protoc"},{"key":"2023051919002502700_B22","unstructured":"Schile\n              AJ\n            \n          . Jaxpheno12: type 1 diabetes incidence and other phenotypes in NOD\/ShiLtJ mice on a 6% fat diet, 2018. Accessed 10 May 2022. Available from https:\/\/phenome.jax.org\/projects\/Jaxpheno12"},{"key":"2023051919002502700_B23","first-page":"D716","article-title":"Mouse Phenome Database: a data repository and analysis suite for curated primary mouse phenotype data","volume":"48","author":"Bogue","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2023051919002502700_B24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.diabres.2009.06.021","article-title":"No mantle formation in rodent islets \u2013 the prototype of islet revisited","volume":"85","author":"Kharouta","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"2023051919002502700_B25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diabetes.48.5.989","article-title":"Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse","volume":"48","author":"Sreenan","year":"1999","journal-title":"Diabetes"},{"key":"2023051919002502700_B26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/db11-1293","article-title":"Islet \u03b2-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model","volume":"61","author":"Tersey","year":"2012","journal-title":"Diabetes"},{"key":"2023051919002502700_B27","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-020-05115-6","article-title":"Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis","volume":"63","author":"Leete","year":"2020","journal-title":"Diabetologia"},{"key":"2023051919002502700_B28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2337\/dc15-2849","article-title":"Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes","volume":"39","author":"Sims","year":"2016","journal-title":"Diabetes Care"},{"key":"2023051919002502700_B29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1152\/physrev.00008.2017","article-title":"Pancreatic \u03b2-cell electrical activity and insulin secretion: of mice and men","volume":"98","author":"Rorsman","year":"2018","journal-title":"Physiol Rev"},{"key":"2023051919002502700_B30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s13238-014-0075-7","article-title":"Alterations of the Ca2+ signaling pathway in pancreatic beta-cells isolated from db\/db mice","volume":"5","author":"Liang","year":"2014","journal-title":"Protein Cell"},{"key":"2023051919002502700_B31","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/s41467-021-25887-8","article-title":"Author correction: Intravital imaging of islet Ca2+ dynamics reveals enhanced \u03b2 cell connectivity after bariatric surgery in mice","volume":"12","author":"Akalestou","year":"2021","journal-title":"Nat Commun"},{"key":"2023051919002502700_B32","doi-asserted-by":"crossref","first-page":"e78483","DOI":"10.1371\/journal.pone.0078483","article-title":"IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes","volume":"8","author":"Diaz-de-Durana","year":"2013","journal-title":"PLoS One"},{"key":"2023051919002502700_B33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2337\/db13-0204","article-title":"Soluble factors secreted by T cells promote \u03b2-cell proliferation","volume":"63","author":"Dirice","year":"2014","journal-title":"Diabetes"},{"key":"2023051919002502700_B34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"},{"key":"2023051919002502700_B35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fendo.2018.00051","article-title":"The role of NOD mice in type 1 diabetes research: lessons from the past and recommendations for the future","volume":"9","author":"Chen","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023051919002502700_B36","doi-asserted-by":"crossref","first-page":"E7776","DOI":"10.1073\/pnas.1707381114","article-title":"Imaging the emergence and natural progression of spontaneous autoimmune diabetes","volume":"114","author":"Mohan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023051919002502700_B37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3389\/fendo.2018.00532","article-title":"\u03b2-Cell failure or \u03b2-cell abuse?","volume":"9","author":"Erion","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023051919002502700_B38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2023051919002502700_B39","doi-asserted-by":"crossref","first-page":"e4318","DOI":"10.1210\/clinem\/dgab463","article-title":"Proinsulin to C-peptide ratio in the first year after diagnosis of type 1 diabetes","volume":"106","author":"Freese","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023051919002502700_B40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ceca.2015.03.002","article-title":"Stress-induced dissociations between intracellular calcium signaling and insulin secretion in pancreatic islets","volume":"57","author":"Qureshi","year":"2015","journal-title":"Cell Calcium"},{"key":"2023051919002502700_B41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db15-0792","article-title":"Pancreatic \u03b2-cell adaptive plasticity in obesity increases insulin production but adversely affects secretory function","volume":"65","author":"Alarcon","year":"2016","journal-title":"Diabetes"},{"key":"2023051919002502700_B42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/diab.43.4.511","article-title":"What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism","volume":"43","author":"Rhodes","year":"1994","journal-title":"Diabetes"},{"key":"2023051919002502700_B43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2362.1973.tb02203.x","article-title":"In vitro studies of the rate of proinsulin and insulin turnover in seven human insulinomas","volume":"3","author":"Creutzfeldt","year":"1973","journal-title":"Eur J Clin Invest"},{"key":"2023051919002502700_B44","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/s41598-017-05935-4","article-title":"Targeting cellular calcium homeostasis to prevent cytokine-mediated beta cell death","volume":"7","author":"Clark","year":"2017","journal-title":"Sci Rep"},{"key":"2023051919002502700_B45","doi-asserted-by":"crossref","first-page":"e0122044","DOI":"10.1371\/journal.pone.0122044","article-title":"Testing pancreatic islet function at the single cell level by calcium influx with associated marker expression","volume":"10","author":"Kenty","year":"2015","journal-title":"PLoS One"},{"key":"2023051919002502700_B46","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1073\/pnas.0913107107","article-title":"Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5-\/- mice","volume":"107","author":"Colsoul","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023051919002502700_B47","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.2337\/diabetes.54.6.1798","article-title":"Loss of connexin36 channels alters beta-cell coupling, islet synchronization of glucose-induced Ca2+ and insulin oscillations, and basal insulin release","volume":"54","author":"Ravier","year":"2005","journal-title":"Diabetes"},{"key":"2023051919002502700_B48","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/1535370218761662","article-title":"Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus","volume":"243","author":"Fenske","year":"2018","journal-title":"Exp Biol Med (Maywood)"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/72\/6\/769\/703494\/db220482.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/72\/6\/769\/703494\/db220482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T19:01:58Z","timestamp":1684522918000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/72\/6\/769\/148607\/Immunotherapy-With-Low-Dose-IL-2-CD25-Prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db22-0482","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}